Mannkind (MNKD) Cash from Operations Growth (3y) (2013 - 2026)

Mannkind (MNKD) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -5.07%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 33.08%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 16.64%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -7.60%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Mannkind 1.20 Bn 1.07 Bn 82.66 Mn -87.97%

Historic Data

Download Data
DateValue
Mar 31, 2026 -87.97%
Dec 31, 2025 -49.62%
Sep 30, 2025 41.65%
Jun 30, 2025 31.61%
Mar 31, 2025 29.56%
Dec 31, 2024 56.51%
Sep 30, 2024 37.76%
Jun 30, 2024 29.64%
Mar 31, 2024 36.20%
Dec 31, 2023 351.84%
Sep 30, 2023 38.27%
Jun 30, 2023 39.33%
Mar 31, 2023 28.12%
Dec 31, 2022 22.51%
Sep 30, 2022 18.60%
Jun 30, 2022 -17.47%
Mar 31, 2022 -16.31%
Dec 31, 2021 -35.61%
Sep 30, 2021 -2.94%
Jun 30, 2021 7.56%